Planning teams forming as Thermo Fisher completes $7.2bn Patheon acquisition

By Melissa Fassbender

- Last updated on GMT

(iStock/BrianAJackson)
(iStock/BrianAJackson)

Related tags Thermo fisher Thermo fisher scientific Thermo electron Pharmacology

Patheon is “better positioned” to serve clients following the Thermo Fisher Scientific Inc. acquisition, says CDMO president, whose initial focus will be integration.

Thermo Fisher announced its intention​ to purchase the contract development and manufacturing organization (CDMO) Patheon in May of this year. Last month, the company raised approximately $1.5bn​ to fund the acquisition, which was completed at the end of August.

As part of the completed acquisition, Michel Lagarde has transitioned from president of Patheon to president of Thermo Fisher’s pharmaceutical services, which will have about 12,000 employees and serve approximately 800 clients across 70 countries.

In his new role, Lagarde told us his initial focus will be working through the integration planning process.

Our planning teams are currently being formed and will integrate the business in the best way to serve the interests of our clients to offer end-to-end services,”​ he explained.

Lagarde explained that the acquisitions presents the CDMO with the opportunity to leverage Thermo Fisher’s existing offering for pharma and biotech, as well as their global customer base. “It also strengthens our position as the leading CDMO provider​,” he added.

In comparing the two companies, it is evident that both have complementary capabilities​,” said added. “The pharmaceutical and biotechnology industries is fast growing and changing. We are better positioned to offer clients high-quality drug development and manufacturing solutions.”​  

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Webinars

Headlines